Allogene Therapeutics, Inc. (ALLO) Reports In-Line Q2 EPS

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Goldman Sachs (GS) Tops Q2 EPS by $6.60, Beats on Revenue
• Cal-Maine Foods (CALM) PT Lowered to $85 at Stephens
• Kodiak Gas Services Inc (KGS) PT Raised to $90 at Stifel on Multi-Year Growth Potential